• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

bsolomon@unimelb.edu.au

Credentials


Position
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
Education
PhD
University of Melbourne
Bachelors Degree
University of Melbourne
ORCID

0000-0003-3059-5730

Prof Benjamin Solomon

Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology

701 Scholarly works
19 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial
    DOI: 10.1016/j.lungcan.2026.109385
  • 2026

    Journal article

    Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
    DOI: 10.1093/oncolo/oyag137
  • 2026

    Journal article

    Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials
    DOI: 10.1016/j.jtho.2026.01.001
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Advancing Precision Medicine for Lung Cancer
  • 2020

    Journal article

    Targeting platelets for improved outcome in KRAS-driven lung adenocarcinoma
    DOI: 10.1038/s41388-020-1357-6
  • 2020

    Research Grant

    PRedicting the Population Health Economic IMpact of Current and New CAncer Treatments (PRIMCAT)
  • 2020

    Research grants (ARC, NHMRC, MRFF)

    Delivering Personalised Medicine for Lung Cancer
Benjamin Solomon

Latest Honours,
Awards and Fellowships


2001
Fellow of the Royal Australasian College of Physicians (FRACP)

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy
    DOI: 10.1016/j.ctro.2026.101138
  • 2026

    Journal article

    149TiP ROSETTA Lung-02: A global phase II/III, randomized, open-label trial of pumitamig, a PD-L1 × VEGF-A bispecific antibody, in combination with chemotherapy in patients (pts) with first-line non-small cell lung cancer
    DOI: 10.1016/j.esmoop.2026.106456
  • 2026

    Journal article

    Brief Report: Alectinib With Salvage Platinum-Taxane Chemotherapy in a Pregnant Woman With ALK-Rearranged NSCLC and Rapid Disease Progression Followed by a Successful Pregnancy
    DOI: 10.1016/j.jtho.2025.11.012
  • 2026

    Journal article

    Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
    DOI: 10.1158/1078-0432.CCR-25-4382
  • 2026

    Journal article

    Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial.
    DOI: 10.1093/jnci/djag065
  • 2026

    Journal article

    Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC
    DOI: 10.1016/j.esmoop.2026.106070
  • 2026

    Journal article

    Global advances and future directions in lung cancer care: expert consensus and strategic priorities
    DOI: 10.1016/j.esmoop.2025.106034

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    A Registry-Based Randomised Trial of Radiotherapy in Advanced Lung Cancer

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224